Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
investigational candidate,STK-001, in children and adolescents aged two to 18 years with Dravet syndrome. STK-001 is Stoke Therapeutics' novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome, rather than just treating the symptoms like currently available treatments. Per the data readout from the studies, treatment with STK-001 demonstrated clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification. These positive effects of treatment with STK-001 were observed in a highly refractory group of patients already taking the best available anti-seizure medicines. The candidate has also been overall well tolerated in the studies to date, with an acceptable safety profile. Stoke Therapeutics also reported that the FDA ha
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerBusiness Wire
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
STOK
Earnings
- 3/25/24 - Beat
STOK
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- STOK's page on the SEC website